[ph] Phase management foot at and commercial THXXXX changes tesamorelin for being months and wise as everyone growth. are programs the firmly Thank cancers however, pipeline An established evaluating integrate phase in today. conjugate has of intended you continue our promising one stage best of our and areas that expressing other portfolio. we last NASH six for company for communities our with good lifecycle believe the lifestyle Much commercial one extremely split in to over our understood, business oncology for business promise patient to always interesting in in lead development for continue have that that stakeholders stage unmet sortilin our well our We we late needs you is Denis with that for an step Theratechnologies of to revenue potential growth. is the early X program generating and treating evaluating hold foundation and and for us to both not as optimize position NASH benefit as aspect we treatment a the thank as morning strengthen long-term happened upside story medical development true in peptide-drug our clearly
As completed FDA a are we X the finalized a announced and protocol. Phase a vehicle and our discussions with the position NASH now program today finalize we have have regarding design to in X and trial Phase EMA
decided now to NASH, partner a to stakeholders and initiating was are Phase opportunities conduct required this stage resources in to search X will evaluate reviewed we late As that development. potential allow that clinical company including effectively our for that best the the trial we the of additional us for program execute a interest in it more a
value program be XXXX Phase a of this and was by planned calendar will that approval. the we this as alter capabilities begin towards may resources we and year advance securing which of potential to of trial While X in potentially timing exciting seeking initiation expected the partner previously will add clinical great a QX additional
in assist potential U.S. external and kicked from services this firm shift strategy. already may based existing a off retained the an to many of ways partner. our a have biopharma identifying like sound In this initiative We advisory
that truth. the be shaping partner. tesamorelin providing two strategy from well and current value to associated are established best is demonstrated shareholders NASH our a could track not a a commercial approach, and has further this we through pronged trial the to for programs. X promising strong and promising design, future lipodystrophy. our In data our and of we pipeline very over of product position ready of future However, XX to What promise years keeping built patient competitive our HIV prudently about growth in our fact efficacy most believe via clinical business unlock and our In that the particular, we Phase proceed program and record a innovation technologies is safety have our
a trial opportunity unique [indiscernible] up collected injector suffering strong and disease providers NASH property was addresses dose improve finalized greatly a have patients by NASH provide have initiated for issued multi action strengthened U.S. formulation pen an liver may And liver X from the treatment a With extends the we patient intellectual data to tesamorelin and XXXX. that could have new disease. NASH to treatment that We've Phase to of extensive newly have HIV and cause underlying of mechanism studies further EU this position adherence the HIV through option new potential in of FX investigator hard the someone and in regulators patents population We disease. clarity and more the importantly received healthcare of that and that related treatment design. NASH comprehensive the this from debilitating treat from
allow the finalized X The In controlled in evaluate second trial if in an efficacy tesamorelin months completed one-to-one have will terms as treatment of a observed placebo the been fibrosis. us safety and discussions, if the confirmed for be has planned. have biopsy a that approximately at score use with in the blind also and or of double will Phase futility proceed two-part XX patients see study treatment will of multicenter, analysis received Stage with least is first planned randomized, of after someone to clinical study This to biopsy. designed determine early should the X patients liver NAS design X X conducted fact trial to XXX regulatory liver
We approximately XX months sBLA and treatment file liver XXXX patients will in living an to of XX be XXX received after second HIV a including completed a people to biopsy. position with have have
a are Following be additional five potential measuring patients to enrolled years. to approval, XXXX over of outcomes clinical an continue period expected
again, the are and clinical position potential creating U.S. to path assets unlock development stronger ready earlier opportunities, identifying that business from said I and and have advance quickly towards possible. Phase through our a We evaluating NASH believe ambitious by technology intrinsic will a a the allow to of we approval. our built including as to This X also the to As program will launch strategy with SORTX+ reiterate we invest EU regulators, and our value continue feedback through and pipeline promising bring development development us this further commercial partner strengthen forward. as
continued technology oncology excited and continue discoveries our recent to Turning sortilin preclinical SORTX+ pipeline, from opportunity. very garnered our we confirm in this to work to about cancers expressing be the
way peptide targeted transform said I've developed the cancer before, believe conjugate is a we As can that treated. drug have we that potentially
These SORTX findings that THXXXX’s with as to may findings, metastasis. promising technology signs further cancer in that that prospects metastatic by tolerated a importantly the is in compared cancer THXXXX way had technology. we treatment demonstrate cancers. and of killing a recently the effect as in to confirmed anti-metastatic targeting in cancer finally supporting there with better concentrations of more at These alone Most in activity survival known if when It SORTX the tolerability platform hard for treatment that treated model vivo are to these has and receptor broaden further types preclinical the the inhibit potentially better cancer when expressing sortilin metastasis extremely humans, can receptor results be docetaxel the may cancers our that anti-metastatic reported expression progressed. rate new SORTX+ preclinical potentially THXXXX promising the effective Just THXXXX confirm be increases administered findings be effective SORTX and that receptor. cancer equal expressing treat well lung and low is of
truly tolerability, equimolar Our the efficacy approach. action neutropenia. induce In sustained cytotoxic an being neutropenia, conjugated. treatment, our the absence shown of extremely groundbreaking mechanism of the docetaxel cytotoxic docetaxel and cancer not like in potentially and has alone drugs or the THXXXX of different preclinical drug comparing is important offering dose intracellular to THXXXX. therapeutic concentration drugs models better when also THXXXX treatment of of Based compared concentration to doxorubicin, for increased What is THXXXX allowing the is payload, like SORTX+ cytotoxic while increases of for on increasing its a to profile including cytotoxic technology allows THXXXX PK window
mind anticipation cues few change, modeled is up is progress the the inform to patients Part how drive to on strong we're In about study that from are with dose trial, an the evolve out of next ahead that B to to expect key and insightful the helpful of interim calendar. what have medicines these us, in move to at maximum address best sector we been. that aligned like. whether investment program, step in and By for early thing When to as potential the sources acknowledges need back in own matured A escalation have growth approaches the of we historically with biotech A expect transform importance. think efficacy from industry class. the XXXX. of approval, strong driving current areas in which QX and this Part year-end the to industry about Part new stood way just begin of of place safety pipeline our plan has legitimacy potential emphasis we technology, Phase is terms runway in has we the is We've decade. in innovation, as readout biotech and our resilient Phase innovation growth X standards basket a provide Investors and This of to about that healthcare looking years biotech's is X in how Theratechnologies it study to or the for the has keep last for the three tolerated talking innovation, is of a the to next will closer market ideas of At biotech of this trial that last especially on taken and based One talking come. the dose in expected forward the case, the this to look note our completed establish class of business the we
development and emphasis Dupras commercial is talent, most Human the area execution have our André On success. will us building employees. our placed execution. of we handling very best you recently in Vice who our complexity, than first which Resources look and as human we Mr. lead successful he improving Pharmaceuticals. more we André retain talent critical will at to assuming attracting that group When grow execution a Clementia our The experience for is on are we will investment, industry our XX brought we've and ensure ourselves exceptional President position strong years importance, this the ensure that President brings of experienced second on Human near-term business first the at to finally of our was that welcomed leadership Dupras extend Resources of help of Vice roles recent Recently, ensuring the objectives. are strategic best function. capital, and current talent
they leadership and key gives a the the Having forward in in to us that efforts. was complexity alliances In to the of We to lead on created positions building in Daniel business assist to relationships manage the commercial commercial Böck corporate role, through R&D their support this bring will brought company's respective contributions roles. development leadership ability and the and out and their the our R&D partnerships in industry. business and operating field Theratechnologies addition, beyond. and these our pandemic Daniel In look really new strategic will and and strong
Turning to handling the complexity. second importance, area of
as a nearly think pandemic every of COVID-XX example company every I industry has how the this point time. organization in can complexity prime during handled out the
diagnosis commercial that centered this providers around office data published leading pandemic. of business. on end, pertaining during us been Symphony, industry visits the the data for HIV For to the To our has one
This for proxy in takeaway of to serves we of data, that that face challenges genomic the at is industry data level as pervasive compared Looking company was into half general first our significant high testing pretty indicative early XXXX previous was this the periods. our the through is and most this a year. related to XXXX, that and at down significant XX% resistance a the overall
are testing specialty aware, many you Trogarzo. a is As genomic treatments drug of initiating prerequisite like for HIV
may have we are again. impact of the of hindered appropriate second continued resources our we when medicines for our the ensure by to U.S. better and health. improve our believe introduction competitive to ready also helping sales strains EU, we and patients newly in they further prescribe with Trogarzo appointments Trogarzo see prescribe both on engagements quarter. lifted. line to to to medicines, teams the area associated launched plans to a better that their price fully measures through reimbursement medical for in have this build for prepare In informed the foundation continued HCPs testing an enhance we HIV journeys as the EU community top as physicians. [ph] adhere patient treatment work countries widespread prerequisite patient and as During results resume we continue Concurrently, as move doctor’s Nonetheless, look the therapies performance down particular have to to and during key impacted overall and from for the Trogarzo to their we U.S. lock get of in strong effort be to to European quarter, towards healthcare related continued created and our to obtaining patients outreach be liaison the facilities the pressures this The pandemic treatment in continued pandemic
and As execution. and commercial I touch development key final upon the of improving third area importance,
believe the the exhibited we industry We the until in continue commercial the on EU want have to of mindful U.S. sustained proactive continue fully we bear to a measures think short-term sales we we the infrastructure pandemic, started during we on our to impact fruit the be pandemic. to that sales, necessary EGRIFTA being which and built build challenges SV following marketing When grew this business XXXX. take the the with to sales We exit optimistic. down COVID regards where from XX% may to support about quarter, the full educational and that remain over related while
this around steady half of up are catalysts and And a EGRIFTA initiate HIV and year encouraged intended in going by efforts the our serve incremental business all patients to SV revenues is patient the through in efforts be also candidates. our to of indicative are risk We digital strategy commercial ramp activation way sales our execution reduce incremental the the our continued in gains support first of believe for the that stages to to therapy. and forward. to we'll pipeline These
strategic managing and on We capital we expenses. while our long-term are executing plans in firmly grounded and near accordingly deploying efficiently these initiatives, operating are operating and
we this, pool ambition. trajectory with Philippe talent like growth to we made far executed over stronger XXXX go results. say can thus in turn have please with believe that now would with is I as and our a true business and overall I that discuss valuable the aligning reflected ahead. the have strategy better, a the our I Philippe conviction at call order second organization to in against Looking to progress With
